These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28139830)

  • 1. Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer.
    Patrignani P; Sacco A; Sostres C; Bruno A; Dovizio M; Piazuelo E; Di Francesco L; Contursi A; Zucchelli M; Schiavone S; Tacconelli S; Patrono C; Lanas A
    Clin Pharmacol Ther; 2017 Jul; 102(1):52-61. PubMed ID: 28139830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer.
    Krishnan K; Ruffin MT; Normolle D; Shureiqi I; Burney K; Bailey J; Peters-Golden M; Rock CL; Boland CR; Brenner DE
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):447-53. PubMed ID: 11352853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of aspirin on prostaglandin E2 and leukotriene B4 production in human colonic mucosa from cancer patients.
    Frommel TO; Dyavanapalli M; Oldham T; Kazi N; Lietz H; Liao Y; Mobarhan S
    Clin Cancer Res; 1997 Feb; 3(2):209-13. PubMed ID: 9815674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems.
    Tacconelli S; Contursi A; Falcone L; Mucci M; D'Agostino I; Fullone R; Sacco A; Zucchelli M; Bruno A; Ballerini P; Dovizio M; Patrignani P
    Biochem Pharmacol; 2020 Aug; 178():114094. PubMed ID: 32535107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker.
    Sample D; Wargovich M; Fischer SM; Inamdar N; Schwartz P; Wang X; Do KA; Sinicrope FA
    Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):275-9. PubMed ID: 11895877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined activity of COX-1 and COX-2 is increased in non-neoplastic colonic mucosa from colorectal neoplasia patients.
    Jensen TSR; Mahmood B; Damm MB; Backe MB; Dahllöf MS; Poulsen SS; Hansen MB; Bindslev N
    BMC Gastroenterol; 2018 Feb; 18(1):31. PubMed ID: 29486731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals.
    Kovács EG; Katona E; Bereczky Z; Homoródi N; Balogh L; Tóth E; Péterfy H; Kiss RG; Edes I; Muszbek L
    Thromb Res; 2013 Apr; 131(4):320-4. PubMed ID: 23422285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon.
    Barnes CJ; Hamby-Mason RL; Hardman WE; Cameron IL; Speeg KV; Lee M
    Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):311-5. PubMed ID: 10207634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose.
    Ruffin MT; Krishnan K; Rock CL; Normolle D; Vaerten MA; Peters-Golden M; Crowell J; Kelloff G; Boland CR; Brenner DE
    J Natl Cancer Inst; 1997 Aug; 89(15):1152-60. PubMed ID: 9262254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention.
    Ornelas A; Zacharias-Millward N; Menter DG; Davis JS; Lichtenberger L; Hawke D; Hawk E; Vilar E; Bhattacharya P; Millward S
    Cancer Metastasis Rev; 2017 Jun; 36(2):289-303. PubMed ID: 28762014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells.
    Guillem-Llobat P; Dovizio M; Bruno A; Ricciotti E; Cufino V; Sacco A; Grande R; Alberti S; Arena V; Cirillo M; Patrono C; FitzGerald GA; Steinhilber D; Sgambato A; Patrignani P
    Oncotarget; 2016 May; 7(22):32462-77. PubMed ID: 27074574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action.
    Patrignani P; Tacconelli S; Contursi A; Piazuelo E; Bruno A; Nobili S; Mazzei M; Milillo C; Hofling U; Hijos-Mallada G; Sostres C; Lanas A
    Front Pharmacol; 2024; 15():1362217. PubMed ID: 38495101
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
    Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
    Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infection.
    Venerito M; Treiber G; Wex T; Kuester D; Roessner A; Di Mario F; Malfertheiner P
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1225-33. PubMed ID: 16611284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer.
    Chell S; Kaidi A; Williams AC; Paraskeva C
    Biochim Biophys Acta; 2006 Aug; 1766(1):104-19. PubMed ID: 16859832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: a prospective placebo-controlled, double-blind randomized trial.
    Feldman M; Cryer B; Mallat D; Go MF
    Am J Gastroenterol; 2001 Jun; 96(6):1751-7. PubMed ID: 11419825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals.
    Kimura Y; Takano K; Satoh K; Aida K; Kobayashi T; Ozaki Y
    Clin Appl Thromb Hemost; 2014 Sep; 20(6):629-36. PubMed ID: 23677911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mode of action of aspirin as a chemopreventive agent.
    Dovizio M; Bruno A; Tacconelli S; Patrignani P
    Recent Results Cancer Res; 2013; 191():39-65. PubMed ID: 22893199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet activation in patients with colorectal cancer.
    Sciulli MG; Filabozzi P; Tacconelli S; Padovano R; Ricciotti E; Capone ML; Grana M; Carnevale V; Patrignani P
    Prostaglandins Leukot Essent Fatty Acids; 2005 Feb; 72(2):79-83. PubMed ID: 15626589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human pharmacology of naproxen sodium.
    Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.